LLY Stock Recent News

From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity.

Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overweight and suffer from obstructive sleep apnea (OSA).

The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.

Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea. The drug demonstrated effectiveness in reducing the severity of obstructive sleep apnea in patients with obesity, outperforming a placebo in two late-stage clinical trials.

A late-stage trial of Eli Lilly's weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting popular weight loss drugs have the potential to treat conditions other than obesity or type 2 diabetes.

Eli Lilly And Co   (NYSE:LLY) stock was last seen up 2.8% at $767.65, after the pharmaceutical giant said data from two late-stage trials showed its weight loss drug Mounjaro helped reduce irregular breathing in patients with obstructive sleep apnea.

The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand.

The Eli Lilly and Co (NYSE:LLY) weightloss drug Tirzepatide, known as Zepbound and Mounjaro, has also been shown in two trials to help improve the symptoms of sleep apnea. Tirzepatide "meaningfully improved" sleep apnea symptoms in obese people and those with moderate to severe obstructive sleep apnea (OSA), with and without positive airway pressure (PAP) therapy.

Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday.

Eli Lilly & Co. LLY, -0.54% said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. The Phase 3 trial dubbed Surmount-OSA evaluated Zepbound in adults with moderate-to-severe OSA who were not on positive airway pressure, or PAP, therapy for 52 weeks.